#United States #New York #Securities Fraud #Pomerantz LLP #Soleno Therapeutics

Investigation Overview

Pomerantz LLP, a prominent law firm with a notable history in securities litigation, recently announced its investigation into Soleno Therapeutics, Inc. (NASDAQ: SLNO). This investigation seeks to address potentially serious claims regarding the company's business practices and the integrity of its leadership over alleged securities fraud.

Background of Soleno Therapeutics

Soleno Therapeutics is known for developing innovative therapies for metabolic disorders. Its flagship product, Vykat XR, aims to address specific health challenges faced by children. However, recent revelations have raised doubts about the product’s efficacy and safety.

The Allegations

On August 15, 2025, Scorpion Capital published a report highlighting that Vykat XR is overpriced and poses safety risks for children. This report triggered a substantial decline in Soleno’s stock price, which fell by $5.73 per share or 7.41%, bringing the closing price down to $71.63 on the day of the report’s release. Such a decline reflects significant investor concern and potential loss.

The Investigation’s Focus

Pomerantz LLP is focusing on whether Soleno and its executives have acted unlawfully in regards to the claims made by Scorpion Capital. Investors who believe they have been misled or harmed by Soleno's actions are encouraged to join the investigation. This could potentially lead to a class-action lawsuit if sufficient evidence of wrongdoing is found.

What Investors Should Do

Affected investors are urged to contact Danielle Peyton at Pomerantz LLP for further information and to understand their options. The firm’s long-standing commitment to securities law is marked by a history of successful litigation on behalf of investors, emphasizing their dedication to holding corporations accountable for potential misconduct.

Conclusion

As the investigation progresses, the legal landscape surrounding Soleno Therapeutics will continue to develop. Investors should remain vigilant and informed about the unfolding situation, as it may significantly impact their financial decisions. For more updates, interested parties can monitor announcements from Pomerantz LLP and other financial news sources regarding this pivotal case in the biotech sector.

About Pomerantz LLP

Founded over 85 years ago, Pomerantz LLP is a distinguished law firm recognized for its expertise in corporate, securities, and antitrust class action litigation. The firm has played a critical role in landmark securities fraud cases and continues to fight for investor rights. With offices in major cities around the globe, its commitment to providing comprehensive legal representation is well-established.

For more information, visit www.pomlaw.com.